Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 221 to 230 of 890 total matches.

Conjugated Estrogens (Premarin) Vaginal Cream

   
The Medical Letter on Drugs and Therapeutics • Feb 23, 2009  (Issue 1306)
among postmenopausal women and causes itching, dryness and pain with intercourse. Systemic estrogen ...
An old conjugated estrogens vaginal cream (Premarin Vaginal Cream - Wyeth) has been newly approved by the FDA specifically for treatment of moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause. Synthetic conjugated estrogens A vaginal cream (Barr) has also been approved for this indication, but has not yet been marketed.
Med Lett Drugs Ther. 2009 Feb 23;51(1306):14-5 |  Show IntroductionHide Introduction

COVID-19 Update: Pfizer/BioNTech and Moderna Vaccines Authorized for Children ≥6 Months Old

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
. Adverse effects in children 2-4 years old included fatigue, fever, headache, chills, muscle pain ...
The FDA has expanded its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use in children as young as 6 months old. The Pfizer vaccine was previously authorized for use in persons ≥5 years old, and the Moderna vaccine was authorized for use in adults ≥18 years old.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):110-2 |  Show IntroductionHide Introduction

Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
trials and arthralgia, abdominal pain, injection-site reactions, anemia, pyrexia, back pain, arthropathy ...
The injectable interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab was approved earlier for treatment of plaque psoriasis and psoriatic arthritis.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):205-7 |  Show IntroductionHide Introduction

Valdecoxib (Bextra) - a New Cyclooxygenase-2 Inhibitor

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2002  (Issue 1129)
or twice daily was statistically significantly better than placebo in relieving moderate-to-severe pain ...
Valdecoxib (Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx), was recently approved by the FDA for treatment of osteoarthritis, rheumatoid arthritis and primary dysmenorrhea.
Med Lett Drugs Ther. 2002 Apr 29;44(1129):39-41 |  Show IntroductionHide Introduction

Monthly Risedronate (Actonel) for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Sep 08, 2008  (Issue 1294)
— A transient acute-phase reaction including fever, joint pain and/or myalgias has been reported to occur more ...
The bisphosphonate risedronate (Actonel - Procter & Gamble) was recently approved by the FDA in a 150- mg once-monthly oral tablet for prevention and treatment of postmenopausal osteoporosis. The drug is also available for the same indication in 5-mg daily, 35-mg weekly and 75-mg twice-monthly tablets.
Med Lett Drugs Ther. 2008 Sep 8;50(1294):69-70 |  Show IntroductionHide Introduction

Alvimopan (Entereg) for Postoperative Ileus

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
a bowel resection, postoperative pain management regimens typically include an opioid, which is one ...
The FDA has approved the marketing of alvimopan (Entereg - Adolor/GlaxoSmithKline), a selective muopioid receptor antagonist, for oral treatment of postoperative ileus after bowel resection. The only other drug in this class available in the US is subcutaneously injected methylnaltrexone (Relistor), which is approved for treatment of opioid-induced constipation in patients with advanced illness receiving palliative care.
Med Lett Drugs Ther. 2008 Dec 1;50(1300):93-4 |  Show IntroductionHide Introduction

Obeticholic Acid (Ocaliva) for Primary Biliary Cholangitis

   
The Medical Letter on Drugs and Therapeutics • Mar 27, 2017  (Issue 1517)
, fatigue, abdominal $5700.00 pain, rash, arthralgia Ursodiol (UDCA)2 – generic 250, 500 mg tabs 13-15 mg ...
Obeticholic acid (Ocaliva – Intercept), a farnesoid X receptor agonist, has been approved by the FDA for treatment of primary biliary cholangitis; it is indicated for use in combination with ursodeoxycholic acid (ursodiol, UDCA; Urso, and others) in adults with an inadequate response to UDCA and as monotherapy in adults unable to tolerate UDCA. Obeticholic acid is the second drug to be approved for this indication; UDCA was the first.
Med Lett Drugs Ther. 2017 Mar 27;59(1517):53-5 |  Show IntroductionHide Introduction

Arymo ER - A New Abuse-Deterrent Morphine Formulation

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2017  (Issue 1519)
), a new extended-release, abuse-deterrent tablet formulation of morphine sulfate, for management of pain ...
The FDA has approved Arymo ER (Egalet), a new extended-release, abuse-deterrent tablet formulation of morphine sulfate, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Arymo ER can only be marketed to deter abuse by injection because another single-entity, extended-release morphine product, MorphaBond, which has not been marketed to date, has marketing exclusivity for deterrence of abuse by the intranasal route through October 2018.
Med Lett Drugs Ther. 2017 Apr 24;59(1519):68-9 |  Show IntroductionHide Introduction

Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023  (Issue 1671)
musculoskeletal pain, GI adverse effects, fatigue, decreased appetite, headache, abdominal pain, hot flushes ...
The FDA has approved elacestrant (Orserdu – Stemline), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in postmenopausal women or men who had disease progression following endocrine therapy. Elacestrant is the first oral selective estrogen receptor degrader (SERD) to be approved for treatment of breast cancer; the injectable SERD fulvestrant (Faslodex, and generics) was approved more than 20 years...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):38-40   doi:10.58347/tml.2023.1671d |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024  (Issue 1706)
once/week 70 mg PO once/week Heartburn, esophageal irritation, esophagitis, abdominal pain, diarrhea ...
View the Comparison Table: Some Drugs for Postmenopausal Osteoporosis
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e112-4   doi:10.58347/tml.2024.1706b |  Show IntroductionHide Introduction